MA44207A - Immunoglobulines conjuguées cys80 - Google Patents
Immunoglobulines conjuguées cys80Info
- Publication number
- MA44207A MA44207A MA044207A MA44207A MA44207A MA 44207 A MA44207 A MA 44207A MA 044207 A MA044207 A MA 044207A MA 44207 A MA44207 A MA 44207A MA 44207 A MA44207 A MA 44207A
- Authority
- MA
- Morocco
- Prior art keywords
- immunoglobulins
- chain variable
- cys80
- immunoglobulin
- light chain
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 9
- 102000018358 immunoglobulin Human genes 0.000 title abstract 9
- 229940072221 immunoglobulins Drugs 0.000 title abstract 6
- 150000003573 thiols Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des procédés de génération d'immunoglobulines conjuguées, le procédé comprenant : le décoiffage d'une cystéine à la position d'acide aminé 80 ("cys80") dans une région variable de chaîne légère d'une immunoglobuline, l'immunoglobuline comprenant une région variable de chaîne lourde et la région variable de chaîne légère ; et la conjugaison d'un composé réactif avec thiol avec cys80, le composé réactif avec thiol comprenant un groupe réactif avec thiol. L'invention concerne en outre des molécules de liaison d'antigène et des procédés de génération de celles-ci, des immunoglobulines ainsi que des molécules d'acide nucléique codant pour les immunoglobulines et des cellules hôtes comprenant les molécules d'acide nucléique, des immunoglobulines conjuguées, et des régions variables de chaîne légère pour utilisation dans une immunoglobuline conjuguée.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562182020P | 2015-06-19 | 2015-06-19 | |
PCT/US2016/038041 WO2016205618A1 (fr) | 2015-06-19 | 2016-06-17 | Immunoglobulines conjuguées cys80 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44207A true MA44207A (fr) | 2018-12-26 |
MA44207B1 MA44207B1 (fr) | 2020-11-30 |
Family
ID=56404289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44207A MA44207B1 (fr) | 2015-06-19 | 2016-06-17 | Immunoglobulines conjuguées cys80 |
Country Status (33)
Country | Link |
---|---|
US (3) | US10273310B2 (fr) |
EP (2) | EP3795591B1 (fr) |
JP (2) | JP6823606B2 (fr) |
KR (1) | KR20180021807A (fr) |
CN (1) | CN107949575B (fr) |
AU (1) | AU2016280190B9 (fr) |
BR (1) | BR112017027252A2 (fr) |
CA (1) | CA2989637C (fr) |
CL (1) | CL2017003273A1 (fr) |
CO (1) | CO2017013303A2 (fr) |
CY (1) | CY1123481T1 (fr) |
DK (2) | DK3310816T3 (fr) |
ES (2) | ES2967613T3 (fr) |
HK (1) | HK1252625A1 (fr) |
HR (1) | HRP20201489T1 (fr) |
HU (2) | HUE064407T2 (fr) |
IL (1) | IL256263B (fr) |
LT (1) | LT3310816T (fr) |
MA (1) | MA44207B1 (fr) |
MD (1) | MD3310816T2 (fr) |
MX (1) | MX2017016674A (fr) |
MY (1) | MY189024A (fr) |
PE (1) | PE20180498A1 (fr) |
PH (1) | PH12017502352A1 (fr) |
PL (1) | PL3310816T3 (fr) |
PT (1) | PT3310816T (fr) |
RS (1) | RS60943B1 (fr) |
RU (1) | RU2756101C2 (fr) |
SG (1) | SG10201913935RA (fr) |
SI (1) | SI3310816T1 (fr) |
UA (1) | UA124830C2 (fr) |
WO (1) | WO2016205618A1 (fr) |
ZA (2) | ZA201708619B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022008756A2 (pt) | 2019-11-07 | 2022-07-26 | Eisai R&D Man Co Ltd | Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso |
US20230137966A1 (en) * | 2020-02-12 | 2023-05-04 | Eli Lilly And Company | Crystallization of Antibodies or Antigen-Binding Fragments |
IL298053A (en) | 2020-06-05 | 2023-01-01 | Eisai R&D Man Co Ltd | Antibody-drug conjugates against bcma and methods of use |
CN112694521B (zh) * | 2020-12-02 | 2023-01-17 | 杭州百凌生物科技有限公司 | 一种人工多肽lh、其抗体及在病理检测中的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL193352B1 (pl) * | 1998-04-28 | 2007-02-28 | Applied Research Systems | Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna |
US6904369B1 (en) * | 2000-06-29 | 2005-06-07 | The Trustees Of Columbia University In The City Of New York | Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor |
US7402409B2 (en) | 2003-01-23 | 2008-07-22 | Epitomics, Inc. | Cell fusion method |
CA2533830A1 (fr) * | 2003-08-07 | 2005-02-24 | Epitomics, Inc. | Methodes destinees a humaniser des anticorps monoclonaux de lapin |
WO2006017759A2 (fr) * | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Anticorps fixant le marqueur specifique des cellules endotheliales (tem1) et leurs utilisations |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
PT2164868E (pt) * | 2007-05-04 | 2015-08-04 | Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa | Domínios variáveis de anticorpos de coelho manipulados e suas utilizações |
NZ601583A (en) * | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
CA2711736A1 (fr) * | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Anticorps obtenus par la cysteine pour conjugaison specifique d'un site |
CA2718942A1 (fr) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Conjugues auristatine-lieur de medicament |
WO2010118203A2 (fr) | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Molécules de liaison à l'endosialine |
BR112012030311A2 (pt) * | 2010-06-08 | 2017-01-24 | Genentech Inc | anticorpo |
JP5913307B2 (ja) * | 2010-07-12 | 2016-04-27 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 多機能性抗体複合体 |
CN102008732B (zh) * | 2010-11-08 | 2012-10-24 | 武汉华耀生物医药有限公司 | 一种叶酸偶联抗体药物及其制备方法与应用 |
WO2014031476A1 (fr) * | 2012-08-21 | 2014-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps monoclonaux spécifiques au domaine de la mésothéline et utilisation de ces derniers |
KR20190121874A (ko) | 2012-08-29 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
EP3892294A1 (fr) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Procédés et compositions de conjugaison d'anticorps spécifique à un site |
-
2016
- 2016-06-17 JP JP2017565751A patent/JP6823606B2/ja active Active
- 2016-06-17 EP EP20192124.4A patent/EP3795591B1/fr active Active
- 2016-06-17 CN CN201680035726.6A patent/CN107949575B/zh active Active
- 2016-06-17 UA UAA201713079A patent/UA124830C2/uk unknown
- 2016-06-17 PE PE2017002753A patent/PE20180498A1/es unknown
- 2016-06-17 PL PL16736952T patent/PL3310816T3/pl unknown
- 2016-06-17 US US15/185,879 patent/US10273310B2/en active Active
- 2016-06-17 BR BR112017027252-0A patent/BR112017027252A2/pt active Search and Examination
- 2016-06-17 MX MX2017016674A patent/MX2017016674A/es unknown
- 2016-06-17 LT LTEP16736952.9T patent/LT3310816T/lt unknown
- 2016-06-17 SI SI201630933T patent/SI3310816T1/sl unknown
- 2016-06-17 CA CA2989637A patent/CA2989637C/fr active Active
- 2016-06-17 RS RS20201246A patent/RS60943B1/sr unknown
- 2016-06-17 MD MDE20180417T patent/MD3310816T2/ro unknown
- 2016-06-17 WO PCT/US2016/038041 patent/WO2016205618A1/fr active Application Filing
- 2016-06-17 SG SG10201913935RA patent/SG10201913935RA/en unknown
- 2016-06-17 DK DK16736952.9T patent/DK3310816T3/da active
- 2016-06-17 HU HUE20192124A patent/HUE064407T2/hu unknown
- 2016-06-17 MA MA44207A patent/MA44207B1/fr unknown
- 2016-06-17 HU HUE16736952A patent/HUE051315T2/hu unknown
- 2016-06-17 PT PT167369529T patent/PT3310816T/pt unknown
- 2016-06-17 ES ES20192124T patent/ES2967613T3/es active Active
- 2016-06-17 ES ES16736952T patent/ES2829251T3/es active Active
- 2016-06-17 DK DK20192124.4T patent/DK3795591T3/da active
- 2016-06-17 RU RU2017146220A patent/RU2756101C2/ru active
- 2016-06-17 EP EP16736952.9A patent/EP3310816B1/fr active Active
- 2016-06-17 AU AU2016280190A patent/AU2016280190B9/en active Active
- 2016-06-17 MY MYPI2017001842A patent/MY189024A/en unknown
- 2016-06-17 KR KR1020187001769A patent/KR20180021807A/ko not_active Application Discontinuation
-
2017
- 2017-12-12 IL IL256263A patent/IL256263B/en unknown
- 2017-12-18 PH PH12017502352A patent/PH12017502352A1/en unknown
- 2017-12-18 ZA ZA2017/08619A patent/ZA201708619B/en unknown
- 2017-12-19 CL CL2017003273A patent/CL2017003273A1/es unknown
- 2017-12-22 CO CONC2017/0013303A patent/CO2017013303A2/es unknown
-
2018
- 2018-09-17 HK HK18111926.6A patent/HK1252625A1/zh unknown
-
2019
- 2019-03-14 US US16/353,326 patent/US11129904B2/en active Active
-
2020
- 2020-07-28 JP JP2020127204A patent/JP7042876B2/ja active Active
- 2020-09-18 HR HRP20201489TT patent/HRP20201489T1/hr unknown
- 2020-10-20 CY CY20201100992T patent/CY1123481T1/el unknown
-
2021
- 2021-03-29 ZA ZA2021/02093A patent/ZA202102093B/en unknown
- 2021-09-02 US US17/464,815 patent/US20230001004A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49599A1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
NZ739721A (en) | Antigen binding constructs to target molecules | |
MA44207A (fr) | Immunoglobulines conjuguées cys80 | |
PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
EA201791742A1 (ru) | Антитела, направленные против гена-3 активации лимфоцитов (lag-3) | |
MA40510A (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t | |
EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
BR112015026823A2 (pt) | Polipeptídeo de cadeia pesada de imunoglobulina isolada, polipeptídeo de cadeia leve de imunoglobulina isolada, sequência de ácido nucleico isolada ou purificada, vetor, agente de ligação de proteína de morte-1 programada (pd-1) isolada, célula isolada, composição, e uso do agente de ligação da pd-1 isolada | |
PH12014501927A1 (en) | Antibodies to matrix metalloproteinase 9 | |
PH12014502184A1 (en) | Anti-hla-b* 27 antibodies and uses thereof | |
MA40972B1 (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 | |
EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
MX2009006891A (es) | Anticuerpos cd44. | |
PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
EA201892063A1 (ru) | МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
MX2021001672A (es) | Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car. | |
CA3148491A1 (fr) | Anticorps anti-il17a humanise et son utilisation | |
EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
EA202092981A1 (ru) | Антитела к l1cam и их применение | |
EA202092769A1 (ru) | Антитела против cd63, их конъюгаты и применения | |
MA51717B1 (fr) | Anticorps anti-cd63, conjugués et leurs utilisations |